Is Biogen Getting Desperate?

Two drug companies that have made brain science their mission -- Biogen (NASDAQ:BIIB) and Sage Therapeutics (NASDAQ:SAGE) -- announced on Nov. 27 that they've teamed up to advance a potential treatment for depression. For Sage, it's gaining an influx of cash and an experienced partner in bringing neurology drugs to market. For Biogen, a company whose stock is down 17% year to date, it may be a shot in the dark to try and find growth and optimism anywhere it can.